Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11078
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKoh, Shir Linen
dc.contributor.authorAger, Eleanor Ien
dc.contributor.authorChristophi, Christopheren
dc.date.accessioned2015-05-16T00:39:26Z
dc.date.available2015-05-16T00:39:26Z
dc.date.issued2010-11-01en
dc.identifier.citationLiver International : Official Journal of the International Association For the Study of the Liver; 30(10): 1414-26en
dc.identifier.govdoc20633100en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11078en
dc.description.abstractLiver resection is the most effective treatment for primary liver tumours and metastasis to the liver, and remains the only potentially long-term curative therapy for patients with colorectal cancer (CRC) liver metastases. Nevertheless, there is a significant incidence of tumour recurrence following liver resection. Cellular and molecular changes resulting from resection and the subsequent liver regeneration process may influence the kinetics of tumour growth, contributing to recurrence. Although commonly associated with the systemic homeostasis of blood pressure, fluid and electrolyte, the renin-angiotensin system (RAS) has recently been shown to play a role in regulating cell proliferation, apoptosis and angiogenesis in local organs as well as in malignancies. An electronic search of the English literature on the role of the RAS in liver regeneration and tumourigenesis was performed using PubMed, with additional relevant articles sourced from reference lists. Studies have shown that the blockade of the RAS pathway stimulates liver regeneration and inhibits tumour progression. An understanding of the role of RAS in liver regeneration and tumourigenesis may enable alternative strategies to improve patient outcome and survival after liver resection. This review will discuss the role of the RAS in liver regeneration and in tumour recurrence post-liver resection. The potential of the RAS as a novel therapeutic target for CRC liver metastases patients undergoing liver resection will be outlined.en
dc.language.isoenen
dc.subject.otherAngiotensin II Type 1 Receptor Blockers.therapeutic useen
dc.subject.otherAngiotensin-Converting Enzyme Inhibitors.therapeutic useen
dc.subject.otherAnimalsen
dc.subject.otherAntineoplastic Agents.therapeutic useen
dc.subject.otherCell Proliferation.drug effectsen
dc.subject.otherChemotherapy, Adjuvanten
dc.subject.otherHepatectomy.adverse effectsen
dc.subject.otherHumansen
dc.subject.otherLiver.drug effects.metabolism.pathology.surgeryen
dc.subject.otherLiver Neoplasms.drug therapy.metabolism.pathology.surgeryen
dc.subject.otherLiver Regeneration.drug effectsen
dc.subject.otherNeoplasm Recurrence, Local.etiology.metabolism.pathology.prevention & controlen
dc.subject.otherRenin-Angiotensin System.drug effectsen
dc.subject.otherTreatment Outcomeen
dc.titleLiver regeneration and tumour stimulation: implications of the renin-angiotensin system.en
dc.typeJournal Articleen
dc.identifier.journaltitleLiver international : official journal of the International Association for the Study of the Liveren
dc.identifier.affiliationAustin Health, Department of Surgery, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1111/j.1478-3231.2010.02306.xen
dc.description.pages1414-26en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/20633100en
dc.type.austinJournal Articleen
local.name.researcherChristophi, Christopher
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptSurgery-
crisitem.author.deptHepatopancreatobiliary Surgery-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

30
checked on Nov 29, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.